within Pharmacolibrary.Drugs.ATC.B;

model B05CB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 300 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,
    adminCount     = 1,
    Vd             = 0.00017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sodium citrate is an alkalinizing agent and anticoagulant used mainly to treat metabolic acidosis, as a buffer in various settings, and as an additive to blood products to prevent coagulation by chelating calcium. It is also used as a urine alkalizer and to treat renal tubular acidosis. Sodium citrate is an approved drug and is widely used in medical settings today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults, as literature with precise PK models reporting specific model parameters (such as compartmental volumes and clearance values) is lacking; parameter values are estimated based on known pharmacokinetic behavior of citrate in humans.</p><h4>References</h4><ol><li><p>Nemec, K, et al., &amp; Lemmens-Gruber, R (2010). Evidence-based intravenous pain treatment with analgesic infusion regimens. <i>Arzneimittel-Forschung</i> 60(5) 256–261. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296282&quot;>10.1055/s-0031-1296282</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20533762/&quot;>https://pubmed.ncbi.nlm.nih.gov/20533762</a></p></li><li><p>Islam, T, &amp; Wolf, G (2009). The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. <i>Cancer biomarkers : section A of Disease markers</i> 5(2) 69–73. DOI:<a href=&quot;https://doi.org/10.3233/CBM-2009-0579&quot;>10.3233/CBM-2009-0579</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19414923/&quot;>https://pubmed.ncbi.nlm.nih.gov/19414923</a></p></li><li><p>Shahin, HI, et al., &amp; Chablani, L (2019). Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 302 126–139. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2019.03.029&quot;>10.1016/j.jconrel.2019.03.029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30940497/&quot;>https://pubmed.ncbi.nlm.nih.gov/30940497</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B05CB02;
